There was an enrichment of hematological malignancies that were sensitive to AKT and mTOR inhibition, with the greatest degree of sensitivity observed in T-cell acute lymphoblastic leukemia (T-ALL). This evidence concerns the gene AKT1 and T-cell acute lymphoblastic leukemia.